SB 203580 (RWJ 64809) | p38 MAPK 抑制剂 | MCE

来自 : www.medchemexpress.cn/SB-2035. 发布时间：2021-03-24

SB 203580 (preincubated with 0-30 μM for 1 h and cultured for 24 h in the presence of 20 ng/mL IL-2) prevents the IL-2-induced proliferation of primary human T cells, murine CT6 T cells, or BAF F7 B cells with an IC50 of 3-5 μM[1].
SB203580 blocks PKB phosphorylation (IC50 3-5 μM). SB203580 inhibitsthe phosphorylation of Ser473 in a dose-dependent manner in both CT6 and activated human T cells and IL-2-responsive BA/F3 F7 B cells[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

SB 203580 Chemical Structure CAS No. : 152121-47-6 SizePriceStockQuantity Free Sample (0.1-0.5 mg) Apply now 10 mM * 1 mL in DMSO ￥660 In...SB 203580 | RWJ 64809 | SB203580 | SB-203580 | RWJ64809 | RWJ-64809 | p38 MAPK | Autophagy | Mitophagy | Mitochondrial Autophagy | ATP-competitive | SAPK2a | SAPK2b | LCK | GSK3β | PKBα | Inhibitor | inhibitor | inhibitSB 203580 (RWJ 64809) 是一种选择性的，ATP 竞争性的 p38 MAPK 抑制剂，对 SAPK2a/p38 和 SAPK2b/p38β2 的 IC50 分别为 50 nM 和 500 nM。SB 203580 抑制 LCK，GSK3β 和 PKBα，IC50 比 SAPK2a/p38 高 100-500 倍。SB 203580 不抑制JNK活性，是一种自噬 (autophagy) 和线粒体自噬 (mitophagy) 激活剂。- 高纯度，全球文献引用。SB 203580 (RWJ 64809)